Respiratory syncytial virus vaccine, recombinant pre-fusion f protein 3 older adult (rsvpref3 oa)
Brand: Arexvy
PBAC's latest decision on Respiratory syncytial virus vaccine, recombinant pre-fusion f protein 3 older adult (rsvpref3 oa): Noted (2024). Considered for Prevention of RSV-confirmed lower respiratory tract disease (LRTD) in older adults. The submission requested NIP listing for adults aged ≥60 years (TGA indication) or ≥75 years (ATAGI base case).
PBAC outcome
Noted
2024
ICER (AUD/QALY)
—
ICER not stated
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adults aged ≥60 years (TGA indication) or ≥75 years (ATAGI base case) for prevention of RSV-confirmed lower respiratory tract disease. Alternative populations considered: First Nations people aged 60-74 years and adults aged 60-74 years at high risk for severe RSV infection.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Prevention of RSV-confirmed LRTD
Pivotal trial size
3,557 patients
Key trials
AReSVi-006, AReSVi-004, RENOIR, ConquerRSV
Comparator
no vaccine
Economic model
CUA
ICER note
The document text provided is incomplete (ends mid-sentence in consumer comments section). No ICER values are stated in the available text. The submission was a cost-utility analysis versus no vaccine, but the specific ICER figures are not presented in the extracted portion of the PSD.